Clinical Research Directory

Inclusion criteria 1. Pathologically confirmed or highly suspected aPDAC defined as a pancreatic mass on imaging, suspected distant metastases, no features suggestive of a neuroendocrine tumor, and/or clinico-biological abnormalities compatible with the diagnosis of aPDAC, 2. Age ≥ 18 years, 3. Patients with ECOG PS ≥ 2 and clinico-biological features precluding initial therapeutic clinical trial and/or treatment with FOLFIRINOX or gemcitabine + nab-paclitaxel, 4. No prior history of cancer, except: in situ breast, cervix cancer, or basal cell carcinoma and/or complete remission for more than 3 years from another cancer. 5. Registration in France with the French National Health Care System (CMU included) 6. Patient able to comply with study protocol requirements in the view of the investigator, 7. Before patient registration, written informed consent must be obtained according to ICH/GCP and national/local regulations, 8. Patients requiring at least two components of the integrative care program (pain management, nutritional management, pathological assessment or imaging, and endoscopy/stent). Exclusion criteria: 1. Any medical, psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow- up schedule; those conditions should be discussed with the patient before registration in the trial, 2. Patient protected by law, 3. Pregnant or breast feeding women